Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 4 drugs
Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only...
Approved
Investigational
Matched Synonyms: … erenumab-aooe
Matched Name: … Erenumab
Matched Description: … In particular, erenumab-aooe is a human immunoglobulin G2 monoclonal antibody that has high affinity ... Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to ... Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the …
Matched Categories: … erenumab ... Amino Acids, Peptides, and Proteins …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. erenumab, fremanezumab, galcanezumab), rimegepant and ubrogepant are...
Approved
Investigational
Matched Description: … [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] are the only members of the ... [L11974] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... "gepants" family of medications remaining in development, and the only CGRP antagonists that possess …
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years. ... [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related ... of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and
Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist...
Approved
Investigational
Matched Description: … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and ... [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. ... oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying all 4 drugs